Insulin-like growth factor-1 and cognitive health: Exploring cellular, preclinical, and clinical dimensions

Cellas A Hayes; Destiny Wilson; Miguel A De Leon; Mubarak Jolayemi Mustapha; Sharon Morales; Michelle C Odden; Nicole M Ashpole

doi:10.1016/j.yfrne.2024.101161

Insulin-like growth factor-1 and cognitive health: Exploring cellular, preclinical, and clinical dimensions

Front Neuroendocrinol. 2024 Nov 12:76:101161. doi: 10.1016/j.yfrne.2024.101161. Online ahead of print.

Authors

Cellas A Hayes¹, Destiny Wilson², Miguel A De Leon², Mubarak Jolayemi Mustapha³, Sharon Morales⁴, Michelle C Odden⁵, Nicole M Ashpole²

Affiliations

¹ Department of Epidemiology and Population Health, School of Medicine, Stanford University, Stanford, CA 94305, USA; Department of Biomolecular Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, USA. Electronic address: cahayes3@stanford.edu.
² Department of Biomolecular Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, USA.
³ Faculty of Basic Medical Sciences, University of Ilorin, Ilorin, Nigeria.
⁴ Department of Biomedical Science, School of Medicine, University of California, Riverside, CA 92521, USA.
⁵ Department of Epidemiology and Population Health, School of Medicine, Stanford University, Stanford, CA 94305, USA.

PMID: 39536910
DOI: 10.1016/j.yfrne.2024.101161

Abstract

Age and insulin-like growth factor-1 (IGF-1) have an inverse association with cognitive decline and dementia. IGF-1 is known to have important pleiotropic functions beginning in neurodevelopment and extending into adulthood such as neurogenesis. At the cellular level, IGF-1 has pleiotropic signaling mechanisms through the IGF-1 receptor on neurons and neuroglia to attenuate inflammation, promote myelination, maintain astrocytic functions for homeostatic balances, and neuronal synaptogenesis. In preclinical rodent models of aging and transgenic models of IGF-1, increased IGF-1 improves cognition in a variety of behavioral paradigms along with reducing IGF-1 via knockout models being able to induce cognitive impairment. At the clinical levels, most studies highlight that increased levels of IGF-1 are associated with better cognition. This review provides a comprehensive and up-to-date evaluation of the association between IGF-1 and cognition at the cellular signaling levels, preclinical, and clinical levels.

Keywords: Barnes maze; Cognition; Dementia; Insulin-like growth-factor-1; Mini-mental state examination; Neurodegeneration; Somatomedin C.

Publication types

Review